Josephine M Forbes Selected Research

Advanced Glycation End Products

6/2022	Advanced Glycation End Products (AGEs) and Chronic Kidney Disease: Does the Modern Diet AGE the Kidney?
1/2022	The impact of a modified carbohydrate formula, and its constituents, on glycaemic control and inflammatory markers: A nested mechanistic sub-study.
7/2021	The AGE receptor, OST48 drives podocyte foot process effacement and basement membrane expansion (alters structural composition).
6/2021	Short Duration Alagebrium Chloride Therapy Prediabetes Does Not Inhibit Progression to Autoimmune Diabetes in an Experimental Model.
1/2021	Advanced glycation end products as predictors of renal function in youth with type 1 diabetes.
9/2020	Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes.
10/2019	Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products.
1/2019	Globally elevating the AGE clearance receptor, OST48, does not protect against the development of diabetic kidney disease, despite improving insulin secretion.
6/2016	Diet low in advanced glycation end products increases insulin sensitivity in healthy overweight individuals: a double-blind, randomized, crossover trial.
4/2015	Decrease in circulating concentrations of soluble receptors for advanced glycation end products at the time of seroconversion to autoantibody positivity in children with prediabetes.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Josephine M Forbes Research Topics

Disease

37	Diabetic Nephropathies (Diabetic Nephropathy) 06/2022 - 11/2002
20	Albuminuria 01/2020 - 05/2002
13	Inflammation (Inflammations) 01/2022 - 04/2008
13	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2022 - 08/2005
10	Fibrosis (Cirrhosis) 07/2021 - 09/2003
10	Type 2 Diabetes Mellitus (MODY) 09/2020 - 04/2009
8	Insulin Resistance 01/2022 - 08/2005
7	Obesity 06/2022 - 08/2005
7	Hyperglycemia 11/2020 - 08/2005
7	Diabetes Complications 09/2020 - 03/2003
6	Kidney Diseases (Kidney Disease) 06/2022 - 01/2013
6	Atherosclerosis 11/2020 - 07/2004
5	Cardiovascular Diseases (Cardiovascular Disease) 11/2020 - 08/2013
5	Chronic Disease (Chronic Diseases) 01/2020 - 07/2011
4	Critical Illness (Critically Ill) 01/2022 - 04/2018
4	Hypertension (High Blood Pressure) 11/2021 - 05/2002
4	Body Weight (Weight, Body) 01/2018 - 07/2013
4	Proteinuria 02/2016 - 05/2002
3	Overweight 11/2021 - 06/2016
3	Prediabetic State (Prediabetes) 06/2021 - 04/2015
3	Non-alcoholic Fatty Liver Disease 10/2019 - 04/2014
3	Mitochondrial Diseases (Mitochondrial Disease) 01/2016 - 02/2012
3	Hypertrophy 08/2008 - 09/2003
2	Chronic Renal Insufficiency 06/2022 - 01/2016
2	Necrosis 01/2022 - 01/2017
2	Dyslipidemias (Dyslipidemia) 11/2021 - 09/2010
2	Sclerosis 07/2021 - 09/2010
2	Experimental Diabetes Mellitus 01/2021 - 03/2003
2	Neoplasms (Cancer) 04/2020 - 05/2013
2	Hypoxia (Hypoxemia) 01/2020 - 01/2018
2	Disease Progression 10/2019 - 01/2013
2	Liver Cirrhosis (Hepatic Cirrhosis) 09/2016 - 04/2014
2	Fatty Liver 09/2016 - 04/2014
2	Vascular Diseases (Vascular Disease) 05/2013 - 09/2009
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 05/2013 - 04/2009
1	Autoimmune Diseases (Autoimmune Disease) 01/2022
1	Glucose Intolerance 11/2021
1	Diabetes Mellitus 11/2020
1	Carcinoma (Carcinomatosis) 04/2020

Drug/Important Bio-Agent (IBA)

39	Advanced Glycation End ProductsIBA 06/2022 - 11/2002
14	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 08/2005
13	Receptor for Advanced Glycation End ProductsIBA 01/2022 - 08/2005
11	Proteins (Proteins, Gene)FDA Link 11/2021 - 05/2002
10	Insulin (Novolin)FDA Link 01/2022 - 09/2005
10	alagebriumIBA 06/2021 - 04/2003
7	Dietary Advanced Glycation End ProductsIBA 06/2022 - 03/2010
6	AlbuminsIBA 01/2021 - 09/2003
6	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2016 - 02/2008
6	Superoxides (Superoxide)IBA 04/2014 - 08/2008
5	N(6)-carboxymethyllysine (carboxymethyllysine)IBA 01/2022 - 09/2009
5	CollagenIBA 07/2021 - 08/2004
5	CreatinineIBA 01/2021 - 09/2009
5	Adenosine Triphosphate (ATP)IBA 01/2020 - 03/2010
5	AntioxidantsIBA 08/2013 - 03/2007
4	ChloridesIBA 06/2021 - 08/2008
4	Apolipoproteins E (ApoE)IBA 09/2010 - 07/2004
4	LipidsIBA 09/2010 - 04/2008
3	Blood Glucose (Blood Sugar)IBA 01/2022 - 01/2016
3	Interleukin-6 (Interleukin 6)IBA 01/2022 - 03/2012
3	ApolipoproteinsIBA 01/2021 - 07/2004
3	CholesterolIBA 11/2020 - 04/2008
3	GlycogenIBA 04/2020 - 01/2015
3	Sodium-Glucose Transporter 2 InhibitorsIBA 09/2019 - 01/2016
3	CarbohydratesIBA 01/2019 - 04/2018
3	Biomarkers (Surrogate Marker)IBA 02/2016 - 01/2011
3	Ramipril (Altace)FDA LinkGeneric 01/2014 - 06/2003
3	AngiotensinsIBA 01/2010 - 03/2003
3	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2010 - 02/2008
3	CytokinesIBA 04/2008 - 12/2002
2	C-Reactive ProteinIBA 01/2022 - 01/2017
2	Complement C5a (Complement 5a)IBA 01/2021 - 01/2020
2	Syntex adjuvant formulationIBA 01/2021 - 01/2015
2	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 11/2020 - 09/2010
2	Hormones (Hormone)IBA 09/2020 - 01/2018
2	LigandsIBA 01/2020 - 08/2010
2	Liver GlycogenIBA 01/2017 - 01/2015
2	Triglycerides (Triacylglycerol)IBA 01/2017 - 04/2014
2	Glutathione PeroxidaseIBA 02/2016 - 06/2003
2	empagliflozinIBA 01/2016 - 01/2016
2	Streptozocin (Streptozotocin)FDA Link 09/2010 - 07/2004
2	NF-kappa B (NF-kB)IBA 06/2009 - 08/2004
2	Protein Kinase C-alphaIBA 02/2008 - 11/2004
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2007 - 11/2004
2	Protein Isoforms (Isoforms)IBA 11/2004 - 12/2003
2	Protein Kinase CIBA 11/2004 - 12/2003
2	Fibronectins (Fibronectin)IBA 11/2004 - 12/2002
2	Angiotensin IIIBA 08/2004 - 01/2003
2	pimagedine (aminoguanidine)IBA 07/2004 - 12/2002
1	Dietary ProteinsIBA 11/2021
1	ProteomeIBA 07/2021
1	NPHS2 proteinIBA 07/2021
1	FructosamineIBA 01/2021
1	IncretinsIBA 09/2020
1	Glucagon-Like Peptide 1 (GLP 1)IBA 09/2020
1	Carboplatin (JM8)FDA LinkGeneric 04/2020
1	Mitochondrial Permeability Transition PoreIBA 01/2020
1	alisporivirIBA 01/2020

Therapy/Procedure

17	Therapeutics 06/2022 - 03/2005
3	Glycemic Control 07/2011 - 11/2005
2	Drug Therapy (Chemotherapy) 06/2021 - 04/2020